CABINET - trial - Cabozantinib for NET
Back to basics as I break down a trial
Back to basics as I break down a trial
I discuss RFK Jr.'s confirmation as the US Secretary of Health and Human Services; recent layoffs at the CDC and NIH; and some comments by Harold Varmus in criticism of Jay Bhattacharya.
I discuss the intense media coverage of Trump and the recent decision to cap indirect costs of NIH grants at 15%.
I'm talking about USAID and Elon's team of six engineers; the Bobby Kennedy Jr hearings, particularly concerning Samoa; MMR vaccines; DEI; and NIH funding complaints.
I discuss the recent reduction in indirect funds for NIH grants and lay out why the NIH is a broken funding system.
I discuss the CIA admitting that COVID was a lab leak; Fauci's pardon; NIH meetings; RFK Jr's Senate confirmation hearing; and more.
I discuss Trump's big health care changes: NIH study sections, the MMWR gag order, the US withdrawal from WHO, and more!
The entire healthcare system is broken, it's not just health insurance companies.
Is alcohol healthy for you? I break down everything you need to know about beer, wine, and spirits.
Our 2 hour critical appraisal and ASH review. SO many guest stars
Lecture on systematic review, given by Vinay Prasad MD MPH to students in the UCSF Training in Clinical Research Program, November 2024.
Timothee Olivier and I discuss the top ESMO 2024 abstracts!
AI in healthcare - my latest keynote address
"Masking Mistakes: Lessons from the Science, Policy, and Coverage of COVID-19", the 2024 Brian Shields Lecture on Institutional Ethics which took place on Monday, October 7, 2024 for the Emory Center for Ethics. A conversation with Carlos Del Rio, MD and Vinay Prasad, MD MPH with moderation by Gerard Vong, DPhil, Director of the MA in Bioethics program.
Screening/ Drug efficacy/ Sotorasib/ Adaura and more
My UCSF lecture on driver mutation lung cancer
We break down the best studies from ASCO
Critical Appraisal - My 2 hour ASCO lecture - Day 2 version by Plenary Session
What you need to know in advance of ASCO
Should trials have carbon footprint as an endpoint?
My grand rounds; Beta blockers post MI Single center vs multicenter RCT Masks Boosters and more
I crossover SM podcast; Harvard med students video, Justice curriculum, Masking half the year
Patient advocates, Pharma funding, and is MRD a suitable endpoint
5 reasons that is a bad idea
Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".
They are shitty
Another flawed study Keynote 564. Pembro in adjuvant RCC
What happens when doctors run unethical studies?
Does car T cause secondary AML? We discuss
We talk about 2023 cancer trials